Alpha Tau Medical Ltd. (NASDAQ:DRTS) Receives Average Rating of “Hold” from Brokerages

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) have earned a consensus rating of “Hold” from the six research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $10.75.

A number of equities research analysts have recently weighed in on the stock. Citigroup raised their price target on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Piper Sandler restated a “neutral” rating and issued a $5.00 price target on shares of Alpha Tau Medical in a research note on Wednesday, March 4th. LADENBURG THALM/SH SH raised their price target on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. HC Wainwright raised their price target on shares of Alpha Tau Medical from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Finally, Zacks Research upgraded shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 17th.

Institutional Trading of Alpha Tau Medical

Several hedge funds and other institutional investors have recently made changes to their positions in DRTS. Apella Capital LLC bought a new stake in shares of Alpha Tau Medical during the fourth quarter worth about $1,892,000. Daytona Street Capital LLC acquired a new position in shares of Alpha Tau Medical in the fourth quarter valued at approximately $749,000. Mariner LLC increased its stake in shares of Alpha Tau Medical by 185.8% in the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock valued at $556,000 after buying an additional 80,129 shares during the period. Millennium Management LLC increased its stake in shares of Alpha Tau Medical by 185.7% in the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock valued at $534,000 after buying an additional 70,081 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of Alpha Tau Medical in the first quarter valued at approximately $286,000. 2.65% of the stock is currently owned by institutional investors.

Alpha Tau Medical Stock Performance

Shares of DRTS opened at $10.36 on Monday. Alpha Tau Medical has a 52-week low of $2.78 and a 52-week high of $10.81. The business’s fifty day moving average is $7.65 and its 200-day moving average is $6.34. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.45 and a current ratio of 7.45. The firm has a market cap of $911.78 million, a price-to-earnings ratio of -19.55 and a beta of 1.11.

Alpha Tau Medical (NASDAQ:DRTS) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Equities analysts anticipate that Alpha Tau Medical will post -0.5 EPS for the current fiscal year.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.